Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | — | -$3.61M | -$6.83M | -$11.8M | -$8.31M | -$9.22M |
| Net income | — | -$30.3M | -$6.83M | -$11.7M | -$8.20M | -$8.48M |
| EPS (diluted) | — | -$2.83 | $0.29 | -$0.47 | -$0.32 | -$0.25 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | — | -$4.87M | -$5.44M | -$9.68M | -$8.09M | -$6.35M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $11.2M | $3.09M | $11.6M |
| Total assets | $3.03M | $21.7M | $15.6M | $11.7M | $4.07M | $12.1M |
| Total liabilities | $224K | $242K | $513K | $1.07M | $261K | $488K |
| Shareholders' equity | -$171K | $21.4M | $15.1M | $10.6M | $3.81M | $11.7M |
| Retained earnings | -$183K | -$38.6M | -$45.5M | -$57.2M | -$65.4M | -$73.9M |
| Shares (wtd avg diluted) | 12.0M | 13.6M | 23.3M | 25.1M | 25.8M | 33.8M |
Every figure is extracted from Anebulo Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.